Myelodysplastic Syndromes Clinical Trial
Official title:
An Open Label, Prospective, Stratified, Randomized, Controlled, Multi-Center, Phase IIB Study of the Impact of Thymoglobulin Therapy on Transfusion Needs of Patients With Early Myelodysplastic Syndrome (MDS)
Verified date | March 2003 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Immunosuppressive therapy may improve bone marrow abnormalities and may be effective treatment for myelodysplastic syndrome. It is not yet known whether immunosuppressive therapy is more effective than supportive care in treating myelodysplastic syndrome. PURPOSE: Randomized phase II trial to compare the effectiveness of antithymocyte globulin with that of supportive care in treating patients who have myelodysplastic syndrome.
Status | Completed |
Enrollment | 0 |
Est. completion date | November 2003 |
Est. primary completion date | November 2003 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility | DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed early myelodysplastic syndrome (MDS) with less than 10% bone marrow blasts - Refractory anemia (RA) - RA with excess blasts (RAEB) - Hypocellular myelodysplasia - Low or intermediate-1 prognostic risk - Transfusion-dependent - Need for 2 or more units of red blood cells or platelets per month for 2 or more months prior to study OR - History of prior transfusions and 2 consecutive (at least 21 days apart) hemoglobin levels less than 8.0 g/dL or platelet counts less than 20,000/mm^3 during the past 2 months - Hemoglobin no greater than 12.0 g/dL after prior transfusion - No myelosclerosis occupying more than 30% of bone marrow space - No RA with ringed sideroblasts, RAEB in transformation, or chronic myelomonocytic leukemia - No therapy-related MDS - No history of immune-related hematologic disorder (e.g., idiopathic thrombocytopenic purpura) PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - At least 3 months Hematopoietic: - See Disease Characteristics - No other causes of cytopenia unrelated to MDS (e.g., gastrointestinal blood loss) - Iron present on marrow examination OR - Transferrin saturation at least 20% and ferritin at least 50 ng/mL Hepatic: - Bilirubin no greater than 2 mg/dL OR - SGOT/SGPT no greater than 2 times normal - No active or chronic hepatitis B or C Renal: - Creatinine no greater than 2 mg/dL Cardiovascular: - No symptomatic cardiac disease - No congestive heart failure (even if medically controlled) - No myocardial infarction within the past 6 months Pulmonary: - No severe pulmonary disease - If history of pulmonary insufficiency, must have pO_2 at least 90 mm/Hg on room air or pCO_2 no greater than 40 mm/Hg Other: - No history of unresolved B12 or folate deficiency since diagnosis of MDS - No untreated acute or chronic infection (afebrile for 7 days without antibiotics prior to study) - No active or chronic HIV - No concurrent cytomegalovirus infection - No other malignancy within the past 2 years except adequately treated localized squamous cell or basal cell skin cancer or carcinoma in situ of the cervix - No concurrent drug or alcohol abuse - No significant medical or psychosocial problems - No known allergy to rabbit protein - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 8 weeks since prior biologic agents, colony-stimulating factors, or epoetin alfa for MDS - At least 8 weeks since other prior investigational biologic agents - No prior or concurrent bone marrow transplantation - No concurrent epoetin alfa - No concurrent growth factors except filgrastim (G-CSF) or sargramostim (GM-CSF) for neutropenic fevers - No other concurrent biologic agents Chemotherapy: - At least 8 weeks since prior cytotoxic drugs for MDS - Concurrent chemotherapy for clinical indications of disease progression or leukemic transformation allowed Endocrine therapy: - At least 8 weeks since prior androgenic hormonal therapy for MDS - At least 8 weeks since prior danazol for MDS Radiotherapy: - No prior radiotherapy Surgery: - No prior organ transplantation Other: - At least 8 weeks since prior investigational drugs - At least 8 weeks since prior immunosuppressive drugs or other drugs for MDS - No concurrent immunosuppressive therapy - No other concurrent experimental drugs |
Country | Name | City | State |
---|---|---|---|
Canada | Foothills Hospital | Calgary | Alberta |
Canada | Princess Margaret Hospital | Toronto | Ontario |
Canada | Department of Medicine | Vancouver | British Columbia |
United States | Winship Cancer Institute of Emory University | Atlanta | Georgia |
United States | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland |
United States | Indiana Blood and Marrow Transplant | Beech Grove | Indiana |
United States | Rush Cancer Institute | Chicago | Illinois |
United States | Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio |
United States | Texas Oncology P.A. | Dallas | Texas |
United States | University of Florida Health Science Center | Gainesville | Florida |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Holden Comprehensive Cancer Center | Iowa City | Iowa |
United States | University of Kansas Medical Center | Kansas City | Kansas |
United States | University of Missouri Kansas City School of Medicine | Kansas City | Missouri |
United States | Sylvester Cancer Center, University of Miami | Miami | Florida |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Tulane University School of Medicine | New Orleans | Louisiana |
United States | Mount Sinai Medical Center, NY | New York | New York |
United States | New York Presbyterian Hospital - Cornell Campus | New York | New York |
United States | University of Nebraska Medical Center | Omaha | Nebraska |
United States | James P. Wilmot Cancer Center | Rochester | New York |
United States | Saint Louis University Cancer Center | Saint Louis | Missouri |
United States | Siteman Cancer Center | Saint Louis | Missouri |
United States | H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida |
United States | Veterans Affairs Medical Center - Tampa (Haley) | Tampa | Florida |
United States | New York Medical College | Valhalla | New York |
United States | Washington Cancer Institute | Washington | District of Columbia |
United States | Comprehensive Cancer Center at Wake Forest University | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Genzyme, a Sanofi Company |
United States, Canada,
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Terminated |
NCT04313881 -
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
|
Phase 3 | |
Recruiting |
NCT05088356 -
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
|
Phase 1 | |
Recruiting |
NCT04003220 -
Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker
|
||
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Active, not recruiting |
NCT03755414 -
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
|
Phase 1 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT04866056 -
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
|
Phase 1/Phase 2 | |
Recruiting |
NCT04701229 -
Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes
|
||
Suspended |
NCT04485065 -
Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS
|
Phase 1 | |
Recruiting |
NCT04174547 -
An European Platform for Translational Research in Myelodysplastic Syndromes
|
||
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Completed |
NCT02508870 -
A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
|
Phase 1 | |
Completed |
NCT04543305 -
A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
|
Phase 1 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Recruiting |
NCT05365035 -
A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts
|
Phase 2 | |
Recruiting |
NCT06008405 -
Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy
|
Phase 1 | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Withdrawn |
NCT05170828 -
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
|
Phase 1 |